Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer? drug combo trial shows promise

NCT ID NCT06119217

Disease control Sponsor: Trishula Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer took part. The goal was to see if the new combinations were safe and more effective than chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

194 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Abbreviated Inclusion Criteria: 1. Age 18 years or older, is willing and able to provide informed consent 2. Histologically or cytologically confirmed diagnosis of metastatic PDAC. 3. No prior systemic treatment for metastatic disease. 4. Evidence of measurable disease per RECIST 1.1. 5. Appropriate for treatment with nab-paclitaxel and gemcitabine chemotherapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Abbreviated Exclusion Criteria: 1. History of clinically significant allergy or hypersensitivity to planned study treatment components or to any monoclonal antibody 2. Use of investigational agent within 14 days prior to the first dose of study drug 3. History of autoimmune disease 4. Subject has received live vaccine within 28 days prior to the first dose of study drug 5. Has uncontrolled intercurrent illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm neoplasm Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Investigative SIte

    Hot Springs, Arkansas, 71913, United States

  • Investigative Site

    Seoul, 03722, South Korea

  • Investigative Site

    Seoul, 05505, South Korea

  • Investigative Site

    Seoul, 06351, South Korea

  • Investigative Site

    Seoul, 08308, South Korea

  • Investigative Site

    Barcelona, 08009, Spain

  • Investigative Site

    Barcelona, 08035, Spain

  • Investigative Site

    Madrid, 28040, Spain

  • Investigative Site

    Madrid, 28041, Spain

  • Investigative Site

    Madrid, 28050, Spain

  • Investigative Site

    Majadahonda, 28222, Spain

  • Investigative Site

    Pamplona, 31008, Spain

  • Investigative Site

    Valencia, 46009, Spain

  • Investigative Site

    Zaragoza, 50009, Spain

  • Investigative Site

    Kaohsiung City, 833401, Taiwan

  • Investigative Site

    Taichung, 40447, Taiwan

  • Investigative Site

    Tainan, 70403, Taiwan

  • Investigative Site

    Taipei, 112, Taiwan

  • Investigative Site

    Taoyuan, Taiwan

  • Investigative Site

    Tucson, Arizona, 85704, United States

  • Investigative Site

    Bakersfield, California, 93309, United States

  • Investigative Site

    Fullerton, California, 92835, United States

  • Investigative Site

    Los Angeles, California, 90095, United States

  • Investigative Site

    Denver, Colorado, 80218, United States

  • Investigative Site

    St. Petersburg, Florida, 33705, United States

  • Investigative Site

    West Palm Beach, Florida, 33401, United States

  • Investigative Site

    Atlanta, Georgia, 30318, United States

  • Investigative Site

    Wichita, Kansas, 67214, United States

  • Investigative Site

    Baton Rouge, Louisiana, 70809, United States

  • Investigative Site

    Columbia, Maryland, 21044, United States

  • Investigative Site

    Burnsville, Minnesota, 55337, United States

  • Investigative Site

    Las Vegas, Nevada, 89119, United States

  • Investigative Site

    Florham Park, New Jersey, 07932, United States

  • Investigative Site

    Asheville, North Carolina, 28806, United States

  • Investigative Site

    Columbus, Ohio, 43219, United States

  • Investigative Site

    Eugene, Oregon, 97401, United States

  • Investigative Site

    Portland, Oregon, 97239, United States

  • Investigative Site

    Horsham, Pennsylvania, 19044, United States

  • Investigative Site

    Austin, Texas, 78705, United States

  • Investigative Site

    Dallas, Texas, 75246, United States

  • Investigative Site

    San Antonio, Texas, 78258, United States

  • Investigative Site

    Tyler, Texas, 75702, United States

  • Investigative Site

    Arlington, Virginia, 22205, United States

  • Investigative Site

    Norfolk, Virginia, 23502, United States

  • Investigative Site

    Roanoke, Virginia, 24014, United States

  • Investigative Site

    Milwaukee, Wisconsin, 53226, United States

  • Investigative Site

    Albury, New South Wales, 2640, Australia

  • Investigative Site

    Westmead, New South Wales, 2145, Australia

  • Investigative Site

    Herston, Queensland, 4029, Australia

  • Investigative Site

    Besançon, 25030, France

  • Investigative Site

    Dijon, 21079, France

  • Investigative Site

    Lille, 59000, France

  • Investigative Site

    Paris, 75013, France

  • Investigative Site

    Poitiers, 86021, France

  • Investigative Site

    Genova, 16132, Italy

  • Investigative Site

    Meldola, 47014, Italy

  • Investigative Site

    Milan, 20132, Italy

  • Investigative Site

    Pavia, 27100, Italy

  • Investigative Site

    Puglia, 70124, Italy

  • Investigative Site

    Verona, 37134, Italy

  • Investigative Site

    Goyang-si, 10408, South Korea

  • Investigative Site

    Seongam, 13496, South Korea

  • Investigative Site

    Seongnam-si, 13620, South Korea

  • Investigative Site

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.